James J. Harding, MD

Articles

Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer

November 23rd 2024

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

Zanidatamab in Previously-Treated HER2-Positive (HER2+) Biliary Tract Cancer (BTC): Overall Survival (OS) and Longer Follow-up From the Phase 2b HERIZON-BTC-01 Study

June 27th 2024

Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase 2b HERIZON-BTC-01 trial (NCT04466891), after a median follow-up of 12.4 months, zanidatamab showed encouraging antitumor activity with rapid and durable responses and a manageable safety profile in patients with previously treated HER2+ BTC.

Dr Harding on the Rationale for Targeting FGFR2 in Cholangiocarcinoma and Biliary Tract Cancers

May 23rd 2023

James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers.

Dr. Harding on the Management of Immune-related AEs in Advanced Biliary Tract Cancer

March 14th 2023

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

Dr. Harding on Future Directions in the Treatment of Advanced Biliary Tract Cancers

February 24th 2023

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

Dr. Harding on the Evolution of Frontline Chemotherapy Approaches in Advanced Biliary Tract Cancer

February 23rd 2023

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

Dr. Harding on the Prevalence of TSC1/2 Mutations in GI Cancer

February 22nd 2023

James J. Harding, MD, discusses the prevalence of TSC1 and TSC2 mutations in gastrointestinal cancer, and the need to develop a standard-of-care treatment for patients with these genetic alterations.

Dr. Harding on the Results of the SUMMIT Trial in HER2+ Biliary Tract Cancers

January 17th 2021

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

Dr. Harding on Exciting Research Efforts in the Pipeline for HCC

May 22nd 2020

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Dr. Harding on Exciting Research Efforts in the Pipeline for HCC

May 21st 2020

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Dr. Harding on the Goal of the IMbrave150 trial in HCC

February 7th 2020

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).